Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL
- Sponsor
- MorphoSys AG
- Study ID
- NCT04300803
- Status
- Approved For Marketing
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progression — BIOLOGICALExpanded Access Program, Non-Interventional Study
Study Details
Expanded Access Program (EAP) to provide Tafasitamab (MOR208) to eligible patients with relapsed or refractory Diffuse Large B Cell Lymphoma. Access to MorphoSys´ EAP can be requested by contacting the respective CRO Clinigen ([email protected]).
Key Dates
- Status verified
- May 2020
Related Studies
- Long-term Follow-up of Patients Treated With Genetically Modified Autologous T CellsPHASE2 · Enrolling By Invitation · Autolus Limited · Miami, Florida
- A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell LymphomaPHASE2 · Recruiting · University of Rochester · Rochester, New York
- Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell LymphomaPHASE2 · Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell LymphomaEARLY_PHASE1 · Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey